# Tempus AI to Acquire Personalis for $1.5B to Integrate MRD Cancer Testing

> ma · REPORTED · 2026-07-20

Tempus AI entered into a definitive agreement to acquire Personalis at $16.25 per share, valuing the deal at approximately $1.5 billion, to integrate Personalis' NeXT Personal whole-genome tumor-informed MRD platform into Tempus' AI-enabled precision oncology suite. The deal is expected to close in late 2026 or early 2027 and was unanimously approved by both boards.

About Tempus AI: Tempus AI is a technology company that applies artificial intelligence to advance precision medicine, offering multimodal clinical data, genomics sequencing, and AI-driven analytics to oncologists, pharmaceutical companies, and health systems.

- Company: Tempus AI
- Sector: oncology
- Primary source: https://www.tempus.com/news/pr/tempus-to-acquire-personalis-integrating-mrd/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.